Sekretariat Ditjen Pencegahan DAN P

Sekretariat Ditjen Pencegahan dan Pengendalian Penyakit (Sekretariat Ditjen P2P) is the Secretariat of the Directorate General of Disease Prevention and Control within Indonesia's Ministry of Health. This governmental body is responsible for coordinating and supporting administrative functions related to disease prevention and control programs across the nation. Their role encompasses the development and management of plans, programs, activities, and budgets pertinent to public health initiatives. Additionally, they oversee financial reporting, asset management, quality assurance, risk management, and the formulation of regulations and agreements within the Directorate General. (p2.kemkes.go.id)

While Sekretariat Ditjen P2P does not function as a pharmaceutical wholesaler or distributor, it plays a pivotal role in the procurement and distribution of medical supplies and pharmaceuticals necessary for disease prevention and control efforts. Their activities are integral to ensuring the availability and accessibility of essential medicines and medical devices throughout Indonesia.

As a governmental entity, Sekretariat Ditjen P2P's distribution network is designed to ensure the efficient and equitable distribution of medical supplies and pharmaceuticals across Indonesia. While specific details about their warehouse locations and logistics capabilities are not publicly disclosed, their operations are structured to cover the entire archipelago, facilitating timely delivery to both urban and remote areas. This extensive reach is crucial for maintaining public health standards and effectively managing disease prevention and control programs nationwide.

In Indonesia's pharmaceutical supply chain, Sekretariat Ditjen P2P serves as a central procurement and distribution entity. Although it does not operate as a traditional wholesaler or distributor, its role is critical in sourcing and supplying medical products required for public health initiatives. By coordinating with various suppliers and managing the logistics of medical supplies, Sekretariat Ditjen P2P ensures that essential pharmaceuticals and medical devices are available to healthcare facilities and programs across the country.

Sekretariat Ditjen P2P's sourcing strategy exhibits a high degree of concentration, with a total import value of $5.3 million USD from India over 105 shipments, encompassing five products across three therapeutic categories. The top five imported products—isoniazid, rifampicin, ethambutol, pyrazinamide, and kits—account for 100% of their imports from India. This singular focus on a limited product range suggests a strategic emphasis on specific therapeutic areas, likely driven by prevailing public health needs and disease control priorities.

The reliance on a narrow product portfolio may present risks related to supply chain disruptions or changes in public health priorities. However, this concentration also indicates a targeted approach to addressing specific health challenges, such as tuberculosis, through the procurement of essential medications. The stability of their supplier relationships, particularly with key Indian manufacturers like Lupin Limited and Macleods Pharmaceuticals Limited, is crucial for maintaining a consistent supply of these critical products.

Sekretariat Ditjen P2P's supply chain resilience is closely tied to its partnerships with Indian pharmaceutical manufacturers. The organization's import data reveals engagements with four unique suppliers, with Lupin Limited and Macleods Pharmaceuticals Limited being the primary contributors. This limited supplier base may expose the supply chain to risks associated with geopolitical tensions, regulatory changes, or production issues in India.

To enhance resilience, Sekretariat Ditjen P2P could consider diversifying its supplier base and exploring alternative sources for critical medications. Additionally, ensuring compliance with international Good Manufacturing Practice (GMP) standards among suppliers is essential to maintain product quality and safety. Regular assessments of shipping routes and logistics strategies can further mitigate potential disruptions, ensuring a steady supply of essential pharmaceuticals to meet Indonesia's public health needs.

Sekretariat Ditjen P2P's concentrated sourcing strategy positions it to effectively address specific public health challenges, particularly in the realm of tuberculosis treatment. By focusing on a targeted product portfolio, the organization can streamline procurement processes and ensure the availability of essential medications. However, this approach also necessitates a robust risk management framework to address potential supply chain vulnerabilities.

For Indian pharmaceutical exporters, understanding Sekretariat Ditjen P2P's procurement patterns offers opportunities to align product offerings with Indonesia's public health priorities. Establishing strong partnerships with Sekretariat Ditjen P2P can lead to sustained demand for specific products, provided that exporters can meet the required quality standards and regulatory compliance. Additionally, exploring avenues to diversify the product range and introduce new formulations can further strengthen the relationship and expand market presence within Indonesia.

Indonesia's pharmaceutical import regulations are primarily governed by the Ministry of Trade (MoT) and the National Agency of Drug and Food Control (Badan POM). The MoT oversees the importation of goods, including pharmaceuticals, and issues regulations such as Minister of Trade Regulation No. 8 of 2024, which outlines technical rules for importing products across various industry sectors.

Badan POM is responsible for the pre-market and post-market oversight of drugs and foods in Indonesia. This includes ensuring that imported pharmaceuticals meet safety, efficacy, and quality standards. The Directorate of Drug Registration within Badan POM plays a crucial role in assessing and approving pharmaceutical products for the Indonesian market. (registrasiobat.pom.go.id)

Importers of pharmaceuticals in Indonesia must obtain an import business license (API) from the Ministry of Trade. There are two types of API licenses: API-U (General Importer) for trade and resale, and API-P (Producer Importer) for production inputs only.

Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards. Badan POM recognizes GMP certificates from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certificates from recognized authorities to guarantee product quality and safety. (farmalkes.kemkes.go.id)

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Indonesian standards. This process is overseen by Badan POM to ensure that all medications meet the required safety and efficacy criteria before entering the market. (farmalkes.kemkes.go.id)

Labeling requirements stipulate that all pharmaceutical products display information in Bahasa Indonesia. This includes details such as the product name, active ingredients, dosage instructions, and manufacturer information. Additionally, imported pharmaceuticals must adhere to serialization mandates to facilitate traceability and prevent counterfeit products from entering the supply chain. (farmalkes.kemkes.go.id)

In May 2024, Indonesia's Ministry of Trade issued Regulation No. 8 of 2024, which introduced technical rules governing the importation of products across various industry sectors, including pharmaceuticals. This regulation aimed to streamline import procedures and enhance compliance with international standards.

Subsequently, in August 2025, the Ministry of Trade enacted Regulation No. 20 of 2025, which replaced the previous regulation and introduced stricter procedures for importing chemicals, hazardous substances, and mineral resources. This regulation emphasized the need for mandatory licenses, import approvals, and surveyor reports, with specific provisions for special zones and export schemes.

Sekretariat Ditjen P2P's product strategy focuses on importing essential medications for tuberculosis treatment, including isoniazid, rifampicin, ethambutol, pyrazinamide, and related kits. This targeted approach aligns with Indonesia's public health priorities, addressing the high prevalence of tuberculosis in the country. The demand for these products is driven by the need to provide effective treatment regimens to patients, thereby reducing transmission rates and improving health outcomes.

The emphasis on these specific therapeutic areas reflects a strategic decision to concentrate resources on combating diseases with significant public health impact. By focusing on a limited range of products, Sekretariat Ditjen P2P can streamline procurement processes and ensure the availability of high-quality medications essential for disease control efforts.

Sekretariat Ditjen P2P's sourcing strategy is centered on importing generic formulations from India, a major global supplier of affordable and high-quality generic pharmaceuticals. The organization's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a focus on ready-to-use products that meet the therapeutic needs of patients.

India's established pharmaceutical industry, characterized by its adherence to international quality standards and competitive pricing, makes it a strategic partner for Sekretariat Ditjen P2P. By sourcing from India, Sekretariat Ditjen P2P can ensure a consistent supply of essential medications while managing costs effectively.